Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001551208 | SCV001771668 | uncertain significance | not provided | 2019-11-11 | criteria provided, single submitter | clinical testing | Not observed at a significant frequency in large population cohorts (Lek et al., 2016); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect |
Labcorp Genetics |
RCV001832749 | SCV002152029 | pathogenic | Glycogen storage disease, type II | 2024-01-15 | criteria provided, single submitter | clinical testing | This sequence change replaces threonine, which is neutral and polar, with methionine, which is neutral and non-polar, at codon 234 of the GAA protein (p.Thr234Met). This variant is present in population databases (rs752054011, gnomAD 0.003%). This missense change has been observed in individual(s) with Pompe disease (PMID: 36310651). ClinVar contains an entry for this variant (Variation ID: 1190471). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt GAA protein function with a positive predictive value of 95%. This variant disrupts the p.Thr234 amino acid residue in GAA. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 22644586, 22676651, 34852371). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |
Revvity Omics, |
RCV001551208 | SCV003828463 | uncertain significance | not provided | 2022-12-08 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001832749 | SCV002091953 | uncertain significance | Glycogen storage disease, type II | 2020-03-19 | no assertion criteria provided | clinical testing |